HexylHIBO

CAS No. 334887-43-3

HexylHIBO( —— )

Catalog No. M33866 CAS No. 334887-43-3

HexylHIBO is a type I mGluR antagonist that inhibits mGlu1a and mGlu5a, with Kb values of 140 and 110 μM, respectively.HexylHIBO decreases sEPSC in rats.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 140 In Stock
10MG 207 In Stock
25MG 487 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    HexylHIBO
  • Note
    Research use only, not for human use.
  • Brief Description
    HexylHIBO is a type I mGluR antagonist that inhibits mGlu1a and mGlu5a, with Kb values of 140 and 110 μM, respectively.HexylHIBO decreases sEPSC in rats.
  • Description
    HexylHIBO is a potent group I mGluR antagonist with Kbs of 140 and 110 μM at mGlu1a and mGlu5a receptors, respectively. HexylHIBO decreased sEPSC in rat.
  • In Vitro
    Thus ambient levels of glutamate tonically activate mGluRs and regulate cortical excitability.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Neuroscience
  • Target
    GluR
  • Recptor
    GluR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    334887-43-3
  • Formula Weight
    256.3
  • Molecular Formula
    C12H20N2O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(CCCCC)C1=C(CC(C(O)=O)N)ONC1=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Madsen U, et al. Synthesis and pharmacology of 3-isoxazolol amino acids as selective antagonists at group I metabotropic glutamic acid receptors. J Med Chem. 2001;44(7):1051-1059.?
molnova catalog
related products
  • Cutamesine dihydroch...

    Cutamesine dihydrochloride is a selective?σ1 receptor agonist (IC50: 17.4 nM).

  • FPTQ

    FPTQ is an antagonist of mGluR1.FPTQ is a synthetic isoquinoline derivative.

  • LY2608204

    LY2608204 has been used in trials studying the treatment of Diabetes Mellitus, Type 2.